Mixing It Up: Coadministration of tPA/DNase in Complicated Parapneumonic Pleural Effusions and Empyema

Raju Bishwakarma, Shiwan Shah, Luba Frank, Wei Zhang, Gulshan Sharma, Shawn Nishi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: A recent randomized controlled trial showed 12 serial doses of tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) is safe and effective in managing complicated parapneumonic pleural effusions and empyema (CPEE). However, this regimen is laborious, requiring trained personnel to open/close the chest tube 8 times daily for 3 days. We present our observational data using a simplified regimen of coadministered tPA/DNase. Materials and Methods: This is a retrospective observational study of patients who received coadministered tPA/DNase for CPEE from January 2012 to April 2015 at the University of Texas Medical Branch. Patient demographics, pleural fluid, radiologic and treatment characteristics, and outcomes were collected. Data are presented as proportions and percentages. Our primary outcome was successful treatment without need of surgery and discharge home alive. Secondary outcomes were dose and length of treatment and hospital stay, treatment complications, and 90-day mortality. Results: The study included 39 patients. All pleural effusions were loculated, 59% macroscopically purulent, 50% had a positive organism in Gram stain, and 40% were culture positive. A median of 6 (interquartile range, 3.5 to 6) doses were coadministered mainly via small bore chest tube (≤ 14 Fr in 79%) with a median of 14.5 (interquartile range, 9.5 to 21.5) hospital days. Overall, 85% were successfully treated without need for surgery. Treatment failures occurred in 15%: 3/39 (7%) received surgery; 3/39 (7%) died. Only 1 (2.5%) complication of hemorrhagic pleural effusion resolved after discontinuation of intrapleural treatment. Conclusions: Our study shows intrapleural coadministration of tPA/DNase was effective and safe in management of CPEE.

Original languageEnglish (US)
Pages (from-to)40-47
Number of pages8
JournalJournal of Bronchology and Interventional Pulmonology
Volume24
Issue number1
DOIs
StatePublished - Feb 1 2017

Fingerprint

Pleural Empyema
Deoxyribonucleases
Tissue Plasminogen Activator
Pleural Effusion
Chest Tubes
Length of Stay
Therapeutics
Treatment Failure
Observational Studies
Randomized Controlled Trials
Retrospective Studies
Demography
Mortality

Keywords

  • chest tube
  • complicated parapneumonic effusion
  • deoxyribonuclease
  • empyema
  • fibrinolytic
  • tissue plasminogen activator

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Mixing It Up : Coadministration of tPA/DNase in Complicated Parapneumonic Pleural Effusions and Empyema. / Bishwakarma, Raju; Shah, Shiwan; Frank, Luba; Zhang, Wei; Sharma, Gulshan; Nishi, Shawn.

In: Journal of Bronchology and Interventional Pulmonology, Vol. 24, No. 1, 01.02.2017, p. 40-47.

Research output: Contribution to journalArticle

@article{46b8b105050b420fb966b42a07dcf075,
title = "Mixing It Up: Coadministration of tPA/DNase in Complicated Parapneumonic Pleural Effusions and Empyema",
abstract = "Background: A recent randomized controlled trial showed 12 serial doses of tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) is safe and effective in managing complicated parapneumonic pleural effusions and empyema (CPEE). However, this regimen is laborious, requiring trained personnel to open/close the chest tube 8 times daily for 3 days. We present our observational data using a simplified regimen of coadministered tPA/DNase. Materials and Methods: This is a retrospective observational study of patients who received coadministered tPA/DNase for CPEE from January 2012 to April 2015 at the University of Texas Medical Branch. Patient demographics, pleural fluid, radiologic and treatment characteristics, and outcomes were collected. Data are presented as proportions and percentages. Our primary outcome was successful treatment without need of surgery and discharge home alive. Secondary outcomes were dose and length of treatment and hospital stay, treatment complications, and 90-day mortality. Results: The study included 39 patients. All pleural effusions were loculated, 59{\%} macroscopically purulent, 50{\%} had a positive organism in Gram stain, and 40{\%} were culture positive. A median of 6 (interquartile range, 3.5 to 6) doses were coadministered mainly via small bore chest tube (≤ 14 Fr in 79{\%}) with a median of 14.5 (interquartile range, 9.5 to 21.5) hospital days. Overall, 85{\%} were successfully treated without need for surgery. Treatment failures occurred in 15{\%}: 3/39 (7{\%}) received surgery; 3/39 (7{\%}) died. Only 1 (2.5{\%}) complication of hemorrhagic pleural effusion resolved after discontinuation of intrapleural treatment. Conclusions: Our study shows intrapleural coadministration of tPA/DNase was effective and safe in management of CPEE.",
keywords = "chest tube, complicated parapneumonic effusion, deoxyribonuclease, empyema, fibrinolytic, tissue plasminogen activator",
author = "Raju Bishwakarma and Shiwan Shah and Luba Frank and Wei Zhang and Gulshan Sharma and Shawn Nishi",
year = "2017",
month = "2",
day = "1",
doi = "10.1097/LBR.0000000000000334",
language = "English (US)",
volume = "24",
pages = "40--47",
journal = "Journal of Bronchology and Interventional Pulmonology",
issn = "1944-6586",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Mixing It Up

T2 - Coadministration of tPA/DNase in Complicated Parapneumonic Pleural Effusions and Empyema

AU - Bishwakarma, Raju

AU - Shah, Shiwan

AU - Frank, Luba

AU - Zhang, Wei

AU - Sharma, Gulshan

AU - Nishi, Shawn

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background: A recent randomized controlled trial showed 12 serial doses of tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) is safe and effective in managing complicated parapneumonic pleural effusions and empyema (CPEE). However, this regimen is laborious, requiring trained personnel to open/close the chest tube 8 times daily for 3 days. We present our observational data using a simplified regimen of coadministered tPA/DNase. Materials and Methods: This is a retrospective observational study of patients who received coadministered tPA/DNase for CPEE from January 2012 to April 2015 at the University of Texas Medical Branch. Patient demographics, pleural fluid, radiologic and treatment characteristics, and outcomes were collected. Data are presented as proportions and percentages. Our primary outcome was successful treatment without need of surgery and discharge home alive. Secondary outcomes were dose and length of treatment and hospital stay, treatment complications, and 90-day mortality. Results: The study included 39 patients. All pleural effusions were loculated, 59% macroscopically purulent, 50% had a positive organism in Gram stain, and 40% were culture positive. A median of 6 (interquartile range, 3.5 to 6) doses were coadministered mainly via small bore chest tube (≤ 14 Fr in 79%) with a median of 14.5 (interquartile range, 9.5 to 21.5) hospital days. Overall, 85% were successfully treated without need for surgery. Treatment failures occurred in 15%: 3/39 (7%) received surgery; 3/39 (7%) died. Only 1 (2.5%) complication of hemorrhagic pleural effusion resolved after discontinuation of intrapleural treatment. Conclusions: Our study shows intrapleural coadministration of tPA/DNase was effective and safe in management of CPEE.

AB - Background: A recent randomized controlled trial showed 12 serial doses of tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) is safe and effective in managing complicated parapneumonic pleural effusions and empyema (CPEE). However, this regimen is laborious, requiring trained personnel to open/close the chest tube 8 times daily for 3 days. We present our observational data using a simplified regimen of coadministered tPA/DNase. Materials and Methods: This is a retrospective observational study of patients who received coadministered tPA/DNase for CPEE from January 2012 to April 2015 at the University of Texas Medical Branch. Patient demographics, pleural fluid, radiologic and treatment characteristics, and outcomes were collected. Data are presented as proportions and percentages. Our primary outcome was successful treatment without need of surgery and discharge home alive. Secondary outcomes were dose and length of treatment and hospital stay, treatment complications, and 90-day mortality. Results: The study included 39 patients. All pleural effusions were loculated, 59% macroscopically purulent, 50% had a positive organism in Gram stain, and 40% were culture positive. A median of 6 (interquartile range, 3.5 to 6) doses were coadministered mainly via small bore chest tube (≤ 14 Fr in 79%) with a median of 14.5 (interquartile range, 9.5 to 21.5) hospital days. Overall, 85% were successfully treated without need for surgery. Treatment failures occurred in 15%: 3/39 (7%) received surgery; 3/39 (7%) died. Only 1 (2.5%) complication of hemorrhagic pleural effusion resolved after discontinuation of intrapleural treatment. Conclusions: Our study shows intrapleural coadministration of tPA/DNase was effective and safe in management of CPEE.

KW - chest tube

KW - complicated parapneumonic effusion

KW - deoxyribonuclease

KW - empyema

KW - fibrinolytic

KW - tissue plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=85010065273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010065273&partnerID=8YFLogxK

U2 - 10.1097/LBR.0000000000000334

DO - 10.1097/LBR.0000000000000334

M3 - Article

C2 - 27984384

AN - SCOPUS:85010065273

VL - 24

SP - 40

EP - 47

JO - Journal of Bronchology and Interventional Pulmonology

JF - Journal of Bronchology and Interventional Pulmonology

SN - 1944-6586

IS - 1

ER -